Silverarc Capital Management, LLC Seagen Inc. Transaction History

Silverarc Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $45,656 - $54,137	389 Added 3.66%	11,016 $1.42 Million
Q3 2022 Oct 28, 2022	SELL	$135.27 - $180.11 $4.08 Million - $5.43 Million	-30,160 Reduced 73.95%	10,627 $1.45 Million
Q2 2022 Jul 25, 2022	BUY	$108.81 - $179.33 $3.25 Million - $5.35 Million	29,831 Added 272.28%	40,787 $7.22 Million
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $12,917 - $17,047	108 Added 1.0%	10,956 $1.58 Million
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $128,455 - $171,964	-901 Reduced 7.67%	10,848 $1.68 Million

Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $857,121 - $1.02 Million	6,017 Added 104.97%	11,749 $2 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $98,878 - $117,925	732 Added 14.64%	5,732 $905,000
Q1 2021 May 18, 2021	SELL	$137.51 - $190.8 $345,012 - $478,717	-2,509 Reduced 33.41%	5,000 $694,000
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $1.24 Million - $1.59 Million	7,509 New	7,509 $1.32 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.